BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 36527037)

  • 1. The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis.
    Ding Y; Zheng C; Wei X; Zhang Q; Sun Q
    BMC Public Health; 2022 Dec; 22(1):2363. PubMed ID: 36527037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impacts of diagnosis-intervention packet payment on the providers' behavior of inpatient care-evidence from a national pilot city in China.
    Ding Y; Yin J; Zheng C; Dixon S; Sun Q
    Front Public Health; 2023; 11():1069131. PubMed ID: 37325323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data.
    Yang Y; Zhang Y; Wagner AK; Li H; Shi L; Guan X
    J Glob Health; 2023 Aug; 13():04083. PubMed ID: 37566690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
    Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
    BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of China's healthcare price reforms on traditional Chinese medicine public hospitals in Beijing: an interrupted time-series study.
    Zhu D; Shi X; Nicholas S; Bai Q; He P
    BMJ Open; 2019 Aug; 9(8):e029646. PubMed ID: 31401602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impacts of the zero mark-up drug policy on hospitalization expenses of COPD inpatients in Sichuan province, western China: an interrupted time series analysis.
    Wang J; Li P; Wen J
    BMC Health Serv Res; 2020 Jun; 20(1):519. PubMed ID: 32513170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
    Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
    Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.
    Rong X; Yin J; Duan S; Sun Q; Babar ZU
    BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysis.
    Qin Z; He M; Shen H; Liu S; Xu S; Chen L
    Front Public Health; 2024; 12():1381786. PubMed ID: 38903594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Chinese medical pricing reform on the structure of hospital revenue and healthcare expenditure in county hospital: an interrupted time series analysis.
    Liu M; Jia M; Lin Q; Zhu J; Wang D
    BMC Health Serv Res; 2021 Apr; 21(1):385. PubMed ID: 33902578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of different mark-up drug policies on drug-related expenditures in tertiary public hospitals: an interrupted time series study in Shanghai, China, 2015-2018.
    Wang X; Li F; Wang X; Zhang X; Liu C; Wang D; Wang H; Chen Y
    Biosci Trends; 2020 Mar; 14(1):16-22. PubMed ID: 32092747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data.
    Li BX; Wang YQ; Yi YY; Zhou N; Lv ZX; Ma R; Li X; Yuan N
    BMC Public Health; 2024 May; 24(1):1309. PubMed ID: 38745323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.
    Lan T; Guan L; Pang X; Li X; Yu Q
    J Clin Pharm Ther; 2022 Jan; 47(1):104-111. PubMed ID: 34668203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Financial burden of healthcare for cancer patients with social medical insurance: a multi-centered study in urban China.
    Mao W; Tang S; Zhu Y; Xie Z; Chen W
    Int J Equity Health; 2017 Oct; 16(1):180. PubMed ID: 29017542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of increased reimbursement rates under the new cooperative medical scheme on the financial burden of tuberculosis patients.
    Xin YJ; Xiang L; Jiang JN; Lucas H; Tang SL; Huang F
    Infect Dis Poverty; 2019 Aug; 8(1):67. PubMed ID: 31370909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New cooperative medical scheme decreased financial burden but expanded the gap of income-related inequity: evidence from three provinces in rural China.
    Ma J; Xu J; Zhang Z; Wang J
    Int J Equity Health; 2016 May; 15():72. PubMed ID: 27142618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term and long-term effects of Sanming healthcare system reform on drug-related expenditures for rural patients with cancer in public hospitals: an interrupted time series analysis using segmented regression model in China.
    Fu R; Chen Q; Lin Y; Lin Z; Zheng Z; Hu Z
    BMJ Open; 2023 Jan; 13(1):e065586. PubMed ID: 36604122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of the Full Coverage of Essential Medicines Policy on Utilization and Accessibility of Primary Healthcare Service for Rural Seniors: A Time Series Study in Qidong, China.
    Wang Y; Zhu Y; Shi H; Sun X; Chen N; Li X
    Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31698773
    [No Abstract]   [Full Text] [Related]  

  • 19. Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis.
    Sun Y; Zhu Z; Zhang J; Han P; Qi Y; Wang X; Yang L
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of China's zero markup drug policy on drug costs for managing Parkinson's disease and its complications: an interrupted time series analysis.
    Wang R; Li X; Gu X; Cai Q; Wang Y; Yi ZM; Chen LC
    Front Public Health; 2023; 11():1159119. PubMed ID: 37228740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.